Tagged: Media Coverage

Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.

With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.

How one company seeks to provide hope to cancer patients through more effective treatments.

Genprex’s President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).

Companies are optimizing nonviral delivery methods for commercial use

Austin startup a ripe M&A target for big pharma, one expert says

Inside the industry’s quest for its next crowning achievement in oncology.

A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.

Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.